DelveInsight's "Chemotherapy Induced Nausea and Vomiting (CINV) Market Insights, Epidemiology, and Market Forecast 2032" report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the Chemotherapy Induced Nausea and Vomiting market size, share, trends, and growth opportunities in the seven major markets (7MM) (i.e., the United States, EU4 (Germany, Spain, Italy, France), the United Kingdom and Japan).
The Chemotherapy Induced Nausea and Vomiting market report covers emerging drugs, current treatment practices, market share of individual therapies, and current & forecasted market size from 2019 to 2032. It also evaluates the current treatment practice/algorithm, key drivers & barriers impacting the market growth, and unmet medical needs to curate the best of the opportunities and assess the underlying potential of the market.
Chemotherapy-Induced Nausea and Vomiting (CINV): An Overview
Chemotherapy-Induced Nausea and Vomiting (CINV) are used to describe two of the most common and distressing side effects of cancer chemotherapy, i.e., nausea and vomiting. They have a significant negative impact on the patient’s quality of life and on their ability to comply with therapy. Nausea and vomiting can also result in anorexia, decreased performance status, metabolic imbalance, wound dehiscence, esophageal tears, and nutritional deficiency.
The risk factors for developing CINV can be categorized as patient-related or treatment-related. While there may be some variability in patient risk factors based on the chemotherapy regimen, the common patient factors include age, gender, history of motion sickness and pregnancy-related nausea and vomiting, a history of alcohol use, and emesis with prior chemotherapy. Patients who are younger than 50 years have a higher risk for CINV.
Chemotherapy-Induced Nausea and Vomiting (CINV) Market Key Facts
-
Major pharma giants, such as Helsinn Healthcare and Acacia Pharma, are some of the key players involved in developing therapies for CINV. Estimates suggest that the launch of emerging therapies will positively impact the treatment landscape in the coming years, especially through the entry of advanced combination therapies and intravenous formulations.
-
The French NAVI study found that around 52.4% of patients had at least one episode of nausea or vomiting.
-
Despite the introduction of more effective antiemetics, up to 20% of cancer patients still suffer from moderate to severe CINV.
-
Compared with Italy, Germany, and France presented a greater hospitalization rate following an unplanned visit to the oncology ward or an emergency room access due to CINV.
Chemotherapy Induced Nausea and Vomiting (CINV) Market
The market outlook section of the report helps to build a detailed comprehension of the historical, current, and forecasted Chemotherapy Induced Nausea and Vomiting market size by analyzing the impact of current and emerging pipeline therapies. It also provides a thorough assessment of the market drivers & barriers, unmet needs, and emerging technologies set to impact the market dynamics.
The report gives complete detail of the Chemotherapy Induced Nausea and Vomiting market trend for each marketed drug and mid & late-stage pipeline therapies by evaluating their impact based on the annual cost of therapy, their Mechanism of Action (MOA), Route of Administration (ROA), molecule types, competition with other therapies, brand value, and their impact on the market.
Chemotherapy-Induced Nausea and Vomiting (CINV) Epidemiology Assessment
The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2019 to 2032. It helps to recognize the causes of current and forecasted epidemiology trends by exploring numerous studies and research. The epidemiology section also provides a detailed analysis of diagnosed and prevalent patient pool, future trends, and views of key opinion leaders.
The Report Covers the Chemotherapy Induced Nausea and Vomiting (CINV) Epidemiology Segmented by-
-
Incident Cases of Chemotherapy-Induced Nausea and Vomiting in 7MM (2019–2032)
-
Diagnosed and Treatable Cases of Chemotherapy-Induced Nausea and Vomiting in the 7MM (2019–2032)
-
Type-specific Incident Cases of Chemotherapy-Induced Nausea and Vomiting in 7MM (2019–2032)
Chemotherapy-Induced Nausea and Vomiting (CINV) Drugs Uptake and Pipeline Development Activities
The drug uptake section focuses on the rate of uptake of the potential drugs recently launched in the Chemotherapy Induced Nausea and Vomiting market or expected to be launched during the study period. The analysis covers the Chemotherapy Induced Nausea and Vomiting market uptake by drugs, patient uptake by therapies, and sales of each drug. Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.
The report also covers the Chemotherapy Induced Nausea and Vomiting pipeline development activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyses recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.
Learn How the Chemotherapy Induced Nausea and Vomiting Market Will Evolve and Grow by 2032 @
https://www.delveinsight.com/sample-request/chemotherapy-induced-nausea-and-vomiting-market
Chemotherapy-Induced Nausea and Vomiting (CINV) Therapeutics Analysis
Several major pharma and biotech giants are developing therapies for Chemotherapy Induced Nausea and Vomiting. Currently, Acacia Pharma is leading the therapeutics market with its Chemotherapy Induced Nausea and Vomiting drug candidates in the most advanced stage of clinical development.
The Leading Companies in the Chemotherapy Induced Nausea and Vomiting (CINV) Therapeutics Market Include:
-
Acacia Pharma
-
Camurus
-
LP Pharmaceuticals
-
Skye Bioscience
-
TALLC Corporation
-
Starton Therapeutics
And Many Others
Chemotherapy Induced Nausea and Vomiting (CINV) Drugs Covered in the Report Include:
-
APD403: Acacia Pharma
-
CAM2047: Camurus
-
Fosnetupitant: Helsinn Healthcare
And Many More
The Report Covers the In-depth Assessment of the Emerging Drugs & Key Companies. Download the Sample Report to Learn More @
https://www.delveinsight.com/sample-request/chemotherapy-induced-nausea-and-vomiting-market
Table of Content (TOC)
1. Key Insights
2. Executive Summary
3. Chemotherapy-Induced Nausea and Vomiting Competitive Intelligence Analysis
4. Chemotherapy-Induced Nausea and Vomiting Market Overview at a Glance
5. Chemotherapy-Induced Nausea and Vomiting Disease Background and Overview
6. Chemotherapy-Induced Nausea and Vomiting Patient Journey
7. Chemotherapy Induced Nausea and Vomiting Epidemiology and Patient Population (In the US, EU5, and Japan)
8. Chemotherapy Induced Nausea and Vomiting Treatment Algorithm, Current Treatment, and Medical Practices
9. Chemotherapy Induced Nausea and Vomiting Unmet Needs
10. Key Endpoints of Chemotherapy-Induced Nausea and Vomiting Treatment
11. Chemotherapy-Induced Nausea and Vomiting Marketed Products
12. Chemotherapy Induced Nausea and Vomiting Emerging Drugs and Latest Therapeutic Advances
13. Chemotherapy Induced Nausea and Vomiting Seven Major Market Analysis
14. Attribute Analysis
15. Chemotherapy-Induced Nausea and Vomiting Market Outlook (In US, EU5, and Japan)
16. Chemotherapy-Induced Nausea and Vomiting Access and Reimbursement Overview
17. KOL Views on the Chemotherapy-Induced Nausea and Vomiting Market
18. Chemotherapy-Induced Nausea and Vomiting Market Drivers
19. Chemotherapy Induced Nausea and Vomiting Market Barriers
20. Appendix
21. DelveInsight Capabilities
22. Disclaimer
*The Table of Contents (TOC) is not exhaustive; the final content may vary. Refer to the sample report for the complete table of contents.
Download the Sample PDF to Learn More About the Key Offerings of the Report @
https://www.delveinsight.com/sample-request/chemotherapy-induced-nausea-and-vomiting-market
Connect with us and discover how Delveinsight can help you to identify your potential business partners and investors in the highly dynamic and evolving healthcare market today @ Healthcare Partner Identification
About DelveInsight
DelveInsight is a leading Business Consultant and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Shruti Thakur
Email:Send Email
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/
